ArticleScientific reports2023
Experimental solubility of aripiprazole in supercritical carbon dioxide and modeling.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Optimization of supercritical fluid processes for aripiprazole nanoparticle production using GAS-antisolvent technique and Box-Behnken design.Scientific reports · 2025Article
- Integrating experimental data and machine learning models for solubility prediction of yellow 23 in supercritical carbon dioxide.RSC advances · 2025Article
- Enhancing methyldopa solubility via green supercritical fluid techniques using ethanol co-solvent.Scientific reports · 2025Article
- Enhancing sulfasalazine solubility in supercritical carbon dioxide with ethanol cosolvent: a comprehensive study.Scientific reports · 2025Article
- Mesalazine solubility in supercritical carbon dioxide with and without cosolvent and modeling.Scientific reports · 2025Article
- Determination of the solubility of methyldopa in supercritical carbon dioxide for drug delivery applications: thermal analysis.Scientific reports · 2025Article
- Measuring and modeling the solubility of sulfasalazine in supercritical carbon dioxide to select methods for producing nanoparticles.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The solubility of compounds in supercritical carbon dioxide (SC-[Formula: see text]) has found crucial significance in the fabrication of micro/nano-scaled drugs. In this research, the solubility of Aripiprazole was measured in SC-[Formula: see text] at various temperatures (308-338 K) and pressures (12-30 MPa). Moreover, the experimental solubility results were correlated with several semi-empirical models (Chrastil, Bartle et al., Kumar & Johnston, Menden-Santiago & Teja, Sodeifian et al., and Jouyban et al.) as well as the modified Wilson model. The molar fraction of the drug in SC-[Formula: see text] varied in the range of [Formula: see text] to [Formula: see text]. The solubility highly depended on the operating pressure and temperature. The Chrastil (0.994), Jouyban et al. (0.993) and Sodeifian et al. (0.992) models showed the highest consistency with the obtained values. Furthermore, self-consistency tests were performed on the solubility of Aripiprazole in SC-[Formula: see text]. The approximate total enthalpy ([Formula: see text]), vaporization enthalpy ([Formula: see text]), and solubility enthalpy ([Formula: see text]) were also calculated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.